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ABSTRACT Cerebral malaria (CM) is a disease of the vascular endothelium caused by Plasmodium falciparum. It is character-
ized by parasite sequestration, inflammatory cytokine production, and vascular leakage. A distinguishing feature of P. falci-
parum infection is parasite production and secretion of histidine-rich protein II (HRPII). Plasma HRPII is a diagnostic and
prognostic marker for falciparummalaria. We demonstrate that disruption of a human cerebral microvascular endothelial bar-
rier by P. falciparum-infected erythrocytes depends on expression of HRPII. Purified recombinant or native HRPII can recapitu-
late these effects. HRPII action occurs via activation of the inflammasome, resulting in decreased integrity of tight junctions and
increased endothelial permeability. We propose that HRPII is a virulence factor that may contribute to cerebral malaria by com-
promising endothelial barrier integrity within the central nervous system.
IMPORTANCE Cerebral malaria is a devastating disease. Patients have high levels of the protein HRPII in their blood. We have
found that endothelial cell barriers become leaky when treated with concentrations of HRPII similar to those found in patients.
This result suggests that HRPII may be important in cerebral malaria. Our finding that HRPII functions by causing inflamma-
tion suggests points of intervention for therapy or vaccination against this disease.
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The clinical presentation of malaria ranges from a febrile ill-ness (uncomplicated malaria) to life-threatening disease,
including severe anemia, respiratory distress, and cerebral ma-
laria (CM) (1). Plasmodium falciparum contributes the greatest
morbidity and mortality and is the species that causes CM. CM
results in about 300,000 deaths annually, has a 20% case fatality
rate despite treatment (2–5), and 25% of survivors have long-
term neurological sequelae, including cognitive impairment
(6). CM patients present acutely with decreased sensorium,
progressing to coma. This neurological syndrome is character-
ized by sequestration of infected red blood cells (RBCs) in cere-
brovascular beds, vascular occlusion, inflammation, perivascu-
lar edema, and brain swelling (7–9). Brain swelling and
perivascular edema are strongly associated with death in CM
(9). These manifestations are due in part to breakdown of the
blood-brain barrier (BBB). The BBB regulates access of solutes
and cells to the central nervous system and includes a complex
network of endothelial intercellular junctional proteins (base-
ment membranes), with ensheathment by pericytes, and astro-
cyte end-feet. Disruption of this network results in BBB com-
promise and has been linked to a variety of disease states (11).
Histidine-rich protein II (HRPII) is a unique protein produced
exclusively by P. falciparum; 37% of its amino acid sequence is
histidine, and repeats of histidine plus alanine cover 85% of its
sequence. HRPII is exported by the parasite into the RBC cytosol
(12). As parasites rupture from the host cell, RBC cytosolic com-
ponents, including HRPII, are released into the bloodstream. In
plasma, HRPII can reach 100 g/ml. Since its discovery in 1986
(13), many functions have been ascribed to it, including hemozoin
crystallization, actin formation, T cell suppression, glycosamino-
glycan binding, and procoagulation (14–17).
HRPII has been used as a biomarker for P. falciparum infec-
tion and forms the basis of many current rapid diagnostic tests
(18, 19). On postmortem analyses, HRPII has been observed to
line the endothelial walls of blood vessels (20). Several correl-
ative studies showed an association between plasma HRPII lev-
els and disease severity or development of CM (18, 21–25).
Natural populations of HRPII-deficient Plasmodium falci-
parum parasites exist (26–28), though these tend to be in areas
of low CM incidence.
Due to the established correlation between HRPII levels and
cerebral malaria (18, 24, 25), we questioned whether HRPII
contributes directly to disease pathogenesis. We provide evi-
dence that HRPII is a P. falciparum virulence factor that trig-
gers the inflammasome in vascular endothelial cells. HRPII
binding to brain endothelial cells results in rearrangement of
tight junction proteins and a compromised blood-brain barrier
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(BBB). We propose that HRPII contributes to the pathogenesis
of cerebral malaria.
RESULTS
HRPII compromises endothelial barrier integrity. P. falciparum
parasites as well as soluble parasite components have been shown
to compromise the integrity of an in vitro BBB (29). We assessed
the consequence of HRPII exposure in an in vitro BBB model that
uses a previously established human cerebral microvascular endo-
thelial cell line (hCMEC/D3) shown to behave like primary cells in
their response to barrier perturbation (30). hCMEC/D3 monolay-
ers display apicobasal polarity; the upper chamber of this cellular
model represents the luminal face of a blood vessel (31). P. falci-
parum clone 3D7-parasitized erythrocytes were added to the up-
per chamber, and transendothelial electrical resistance (TEER)
was measured across the endothelial barrier. These parasites in-
duced a time-dependent decrease in resistance (Fig. 1A). In con-
trast, clone Dd2, which contains a deletion of the HRPII gene,
caused minimal change in barrier integrity. Dd2 parasites were
transfected to generate transgenic parasites that ectopically ex-
press HRPII. Integration of the gene for HRPII was confirmed by
PCR, and isolated clones demonstrated an ability to produce
HRPII by Western blotting (see Fig. S1 in the supplemental mate-
rial). Two clones expressing HRPII from independent transfec-
tions compromised barrier integrity (Fig. 1B). Addition of a neu-
tralizing anti-HRPII monoclonal antibody to the upper chamber
confirmed the specific effect of HRPII, as it abolished the barrier
compromise observed using the transfected parasites. Addition of
recombinant, soluble HRPII to wells containing wild-type Dd2
parasites also resulted in barrier compromise. These experiments
demonstrate that HRPII is required for parasites to disrupt endo-
thelial barrier integrity in vitro. Purified HRPII alone (recombi-
nant or isolated from P. falciparum 3D7 parasites) similarly dis-
turbed barrier integrity in a dose-dependent manner, at the
concentrations that are seen in the blood of patients with cerebral
malaria (Fig. 1C). HRPII-mediated barrier compromise took sev-
eral hours to develop and was maximal by 10 to 12 h, consistent
with a requirement for new protein synthesis (see Fig. S2A). Dis-
ruption of the barrier was specific, as antibody blockade of HRPII
abolished the effect. Equimolar concentrations of L-histidine, poly
L-histidine, or peptides for the two main repeats in HRPII did not
recapitulate the effect seen with HRPII (see Fig. S2B).
HRPII induces redistribution of tight junction and adherens
junction proteins. To assess whether HRPII compromises barrier
integrity by altering the localization of BBB junctional proteins,
we performed immunohistochemical analysis of hCMEC/D3
brain microvascular cells, staining for junctional proteins. This
analysis revealed punctate redistribution of the tight junction pro-
tein claudin-5 and the adherens junction protein VE-cadherin
(Fig. 2). The effects were similar to those observed with lipopoly-
saccharide (LPS), a Toll-like receptor 4 (TLR4) agonist that is
known to disrupt the BBB.
HRPII activates an innate immune response in endothelial
cells. The disruption of barrier integrity by HRPII suggested that
endothelial cells recognize and respond to the protein. To inves-
tigate whether this response is mediated by a cell-intrinsic, host
defense signaling response, we measured chemokine and cytokine
transcripts by quantitative reverse transcription-PCR (qRT-PCR)
analysis in hCMEC/D3 cells (32). We detected upregulation of
transcripts within 8 h postexposure to recombinant HRPII, and
the response was distinguished kinetically from that observed with
LPS (Fig. 3A). The expression signature was suggestive of NFB
activation. To assess the involvement of NFB directly, we
blocked its action with short hairpin RNAs (shRNAs) and chem-
ical inhibitors. Two different chemical inhibitors of NFB subunit
p65, triptolide (33) and celastrol (34), ablated the TEER changes
induced by recombinant HRPII and resulted in elevated TEER
and normalized barrier integrity (Fig. 3B). To corroborate the role
of NFB in HRPII-mediated effects on barrier integrity, we si-
lenced expression of the p105 subunit of NFB (see Fig. S3 in the
supplemental material). Again, a decrease in TEER was prevented
(Fig. 3B).
Many cellular host defense pathways activate NFB signaling.
Gene silencing of a common intracellular adaptor, MyD88 (see
Fig. S3 in the supplemental material), performed using three dif-
ferent shRNAs, significantly reduced the HRPII-mediated drop in
TEER (Fig. 3C). These data suggest that HRPII-mediated inflam-
mation is NFB and MyD88 dependent.
HRPII activates the inflammasome.MyD88 is an intracellular
adaptor for several innate immune receptors, with some of these
proteins using MyD88 as an exclusive intracellular adaptor: TLR1
and TLR2 (TLR1/2), TLR2/6, TLR5, TLR7, TLR9, interleukin-1
receptor (IL-1R), and IL-18R (10, 35). Silencing of TLR2, TLR5,
and TLR9 (see Fig. S3 in the supplemental material) did not im-
pact HRPII-mediated endothelial cell barrier disruption (see
Fig. S4). TLR7 silencing could not be achieved and was not eval-
uated. We assessed the impact of IL-1R signaling by neutralizing
its ligand IL-1 with a polyclonal antibody or by using a natural
antagonist to the receptor, IL-1Ra. We demonstrated that HRPII-
mediated change in TEER requires IL-1 activation and signaling
(Fig. 3D). A requirement for caspase-1 was confirmed using two
distinct shRNAs for caspase-1 as well as the caspase-1-specific in-
hibitor YVAD-CMK. Endothelial barriers treated with these re-
agents did not display a change in TEER in the presence of HRPII
(Fig. 3D). HRPII treatment resulted in generation of cleaved
IL-1 as determined by enzyme-linked immunosorbent assay
(ELISA) (Fig. 3E). These data indicate that activation of the in-
flammasome is required for HRPII-mediated BBB disruption.
HRPII binds to and is internalized by hCMEC/D3 cells (see
Fig. S5 in the supplemental material). Internalization could be
required for HRPII action, but further support for this notion
awaits identification of the endothelial receptor for HRPII.
HRPII-induced cell death and loss of barrier integrity are
kinetically distinct phenotypes. Activation of the inflammasome
can cause cell death. To determine whether endothelial cells lose
viability in response to HRPII exposure, we monitored cell death
at various time points. Cells undergoing programmed cell death
display nicked DNA which can be visualized with a terminal
deoxynucleotidyltransferase-mediated dUTP-biotin nick end la-
beling (TUNEL) stain. HRPII-treated cells showed no TUNEL
staining at 6 h (when barrier disruption is evident), although nick-
ing of cellular DNA was evident later, at 24 h postexposure
(Fig. 4A). To rule out the possibility that HRPII-mediated loss of
barrier integrity was a consequence of cell death, we reassessed
TEER changes in the presence of a cell death inhibitor, Z-VAD-
FMK. In this experiment, cycloheximide (CHX) served as a posi-
tive control for endothelial cell disruption via apoptosis. In the
presence of Z-VAD-FMK, cell death (not shown) and barrier leak-
age (Fig. 4B) mediated by CHX was prevented. Gamma interferon
(IFN-) causes a rearrangement of junctional proteins (36) and
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FIG 1 HRPII is both necessary and sufficient to compromise the integrity of an in vitro endothelial barrier. TEER was measured across an hCMEC/D3
monolayer over time, and components for assessment were added to the upper chamber (1-ml volume). (A) 108 uninfected RBCs or Plasmodium falciparum
strain Dd2 (which does not produce HRPII) or strain 3D7 (which produces HRPII) cells were added to the model BBB. All values are relative to resistance
measurements at time zero. Data are mean values standard errors of the means (SEM) of results from 2 biological replicates performed in triplicate. Dd2 was
significantly different from 3D7 by one-way analysis of variance (ANOVA) (, P 0.05). (B) Addition of 108 Dd2 parasites, parasites engineered to produce
HRPII (Dd2/gHRPII-1 and Dd2/gHRPII-2), Dd2 parasites with 10 g of added recombinant HRPII (Dd2/rHRPII), or Dd2/gHRPII-1 parasites in the presence
of specific antibody (Dd2/gHRPII/anti-HRPII [HRPII]). Data are mean values SEM of results from 6 replicates from three independent experiments. *, P
0.0001; **, P 0.009 (by one-way ANOVA for differences from Dd2-treated cells). (C) Addition of recombinant purified HRPII (rHRPII) or of HRPII purified
from 3D7 parasites (native HRPII) or in combination with monoclonal anti-HRPII antibody (HRPII) or isotype control (Iso). Data are mean values SEM of
results from a 24-h time point for 4 replicates (most conditions), 6 replicates (antibodies), and 8 replicates (0 and 5 g rHRPII), pooled from five independent
experiments. *, P 0.0001 (by one-way ANOVA for differences from 0 g).
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serves as a control for TEER changes that are not a consequence of
cell death. IFN- compromised barrier integrity even in the pres-
ence of the apoptosis inhibitor. Similarly to the IFN- control,
HRPII-mediated TEER changes were sustained when cells were
treated with Z-VAD-FMK (Fig. 4B). Taken together, these data
indicate that the loss of barrier integrity induced by HRPII is not a
byproduct of cell death.
HRPII treatment upregulates cytoadherence molecules on
endothelial cells in vitro. Cerebral malaria is accompanied by
upregulation of cytoadherence molecules on the vascular endo-
thelium (37–39). We assessed the surface expression of several
relevant adhesion receptors on human brain microvascular endo-
thelial cells after treatment with HRPII. The percentage of cells
expressing ICAM-1 and VCAM-1 was increased upon HRPII
treatment (Fig. 5A and B). In contrast, E-selectin expression was
not increased (Fig. 5C). ICAM-1 expression levels and binding by
parasites are associated with severity of disease (40).
DISCUSSION
BBB breakdown during P. falciparum infection is a significant fea-
ture of CM. The pathophysiology underlying this effect, however,
is poorly understood. Our study has identified HRPII as a parasite
virulence factor that activates the host innate immune system
through an inflammasome-mediated pathway. This causes redis-
tribution of endothelial junctional proteins and increased BBB
permeability. A number of factors, including glycosylphosphati-
dylinositol (GPI), hemozoin, DNA, uric acid crystals, and mi-
crovesicles, have been proposed to activate pattern recognition
receptors and/or inflammasomes. In many of these cases, how-
ever, the bloodstream concentration and therefore the physiolog-
ical relevance are hard to ascertain (41). In contrast, HRPII plasma
levels in malaria patients are easy to measure; incubation of endo-
thelial cells or infusion of mice with physiologically relevant con-
centrations of HRPII led to the effects reported here.
P. falciparum parasites produce two highly homologous
histidine-rich proteins: HRPII and HRPIII. Of the two, HRPII is
produced abundantly, whereas HRPIII accumulates at much
lower levels (42). The Dd2 P. falciparum parasite strain produces
only HRPIII and has a deletion in HRPII. Using this background
strain, we generated transgenic parasites that express HRPII.
Whereas parental Dd2 parasites caused minimal change in TEER
in an in vitro BBB model with human cells, the HRPII-expressing
clones caused a substantial decrease in TEER. HRPII, the major
histidine-rich protein, appears responsible for this action on the
endothelium.
Intracellular and bloodstream functions for HRPII have been
proposed, including digestive vacuole heme sequestration and
procoagulant activity, respectively (14, 17). There are other pro-
teins that can sequester heme even in the absence of HRPs (14, 43),
and the physiological contribution of HRPII to the procoagulant
state seen in falciparum malaria has not been established (17).
Severe malaria and cerebral malaria are the states that have been
associated with high HRPII levels clinically, and it is reasonable to
propose that the most important role of this molecule is in endo-
thelial inflammation. There are field isolates that lack HRPII (26–
28), but it is not known whether patients infected with these
strains have a milder course or diminished progression to CM.
Assessment of transcriptional responses to HRPII suggested
activation of the NFB pathway. Gene silencing and antagonist
experiments supported the idea of a role for MyD88 and NFB in
mediating the HRPII effect. Triptolide decreases expression of
NFB/p65 and increases expression of the cytosolic inhibitor
IB- (33). Celastrol decreases expression and translocation of
NFB/p65 to the nucleus and diminishes cleavage and activation
of IB- (34). In the presence of these inhibitors, the drop in
TEER induced by HRPII was lost. However, despite extensive
analysis, we did not identify an upstream pathogen recognition
receptor. Rather, additional studies suggested involvement of the
IL-1 receptor, as we could block HRPII-mediated barrier disrup-
tion with IL-1RA, a natural antagonist, or with neutralizing anti-
body to IL-1. IL-1 is a cytokine that is activated from its pro-
form by caspase-1. Caspase-1 is auto-catalytically processed when
molecules are brought into proximity by the inflammasome. Con-
sistent with a key role for the inflammasome, the HRPII effect on
TEER was abolished by silencing of caspase-1 or treatment with a
caspase-1 inhibitor.
Inflammasome activation has been previously implicated in
falciparum malaria infections. Opsonization of parasitized red
blood cells as well as of pooled patient sera from P. falciparum
infections was shown to activate the inflammasome in macro-
phages (44). IL-1 also has been detected in histopathological
sections from patients who died of cerebral malaria (45, 46).
The data suggest a model for HRPII action on endothelial cells
(Fig. 6). HRPII accumulates in the bloodstream and binds to vas-
cular endothelium via an unknown receptor. Downstream signal-
FIG 2 HRPII exposure to human cerebral microvascular endothelial cells
results in redistribution of junctional proteins. hCMEC/D3 monolayer cul-
tures were incubated for 24 h with 25 g of BSA or HRPII or with 3 g of LPS
and were stained for tight junction protein claudin-5 and the adherens junc-
tion protein VE-cadherin. Representative images of 4 replicates from 2 inde-
pendent experiments are presented. All images were taken using the same
settings. Bar, 20 m.
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ing allows recruitment of inflammasome components, which ac-
tivate caspase-1, resulting in cleavage of substrates, including pro-
IL-1, yielding mature IL-1. Active IL-1 is secreted, at which
point it can bind to cell surface receptor IL-1R. IL-1R ligation
transmits a MyD88-dependent signal that activates the transcrip-
tion factor NFB. NFB translocates to the nucleus and induces
transcription of many genes, including cytoskeletal components,
which can redistribute tight junction and adherens junction pro-
FIG 3 HRPII activates an inflammatory pathway in human cerebral microvascular endothelial cells. (A) qRT-PCR of chemokine/cytokine mRNA levels of
hCMEC/D3 cells treated with 25g HRPII or BSA for 8 h and 24 h. (B) TEER measurements for in vitro hCMEC/D3 barriers transfected with shRNAs for NFB
(N1 and N3) or a scrambled control (Scrb) for 36 h or incubated with inhibitors for NFB, celastrol (Ce), and triptolide (tr) for 2 h prior to addition of HRPII
(H; 10 g). Data are mean values SEM of results from 6 to 8 replicates pooled from three independent experiments. ***, P 0.0001 (by one-way ANOVA).
(C) TEER measurements for in vitro barriers transfected with shRNAs to MyD88 (M1 and M3 and M5) or a scrambled control (Scrb) for 36 h prior to addition
of recombinant purified HRPII (10 g). Data are mean SEM of results from 6 to 8 replicates pooled from 3 independent experiments. ***, P 0.0001 (by
one-way ANOVA). Results of assessment of knockdown levels are shown in Fig. S2 in the supplemental material. (D) TEER measurements for in vitro barriers
transfected with shRNAs for caspase-1 (C1 and C2) or a scrambled control (Scrb) for 36 h or with IL-1Ra (500 ng), anti-IL-1 (IL-1) (25 ng), or the caspase-1
inhibitor YVAD-CMK (80 M) (C1 Inh) for 1 h prior to treatment with recombinant purified HRPII (10 g; H). Data are mean values SEM of results from
6 to 8 replicates pooled from four independent experiments. ***, P 0.001 (by one-way ANOVA); **, P 0.05 (by one-way ANOVA). (E) Quantitative ELISA
for cleaved IL-1 from cell lysates. Cells were treated for 24 h with HRPII (10 g), LPS (3 g/ml), or IFN- (100 ng/ml) or left untreated. Data represent results
from three biological replicates, each performed in triplicate. *, P 0.0002; **, P 0.0005 (compared to untreated control by unpaired t test).
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teins (47) and can alter surface expression of adhesion receptors
such as ICAM-1 and VCAM-1. Although there have been reports
of IL-1-mediated tight junction rearrangement via an NFB-
independent pathway involving ARNO/Arf6 signaling (48),
HRPII activity has a different time course and requires NFB sig-
naling to impact barrier integrity.
Infection of mice with the rodent malaria parasite strain P. ber-
ghei ANKA serves as a small-animal model for cerebral malaria.
The pathology present in experimental cerebral malaria (ECM) is
similar to that in human cerebral malaria (CM), with notable
exceptions being fewer sequestered infected RBCs and a more ro-
bust infiltration of leukocytes (5, 49). The biological basis of these
differences is controversial and poorly defined (5, 50, 54). Aspects
of HRPII action may explain some differences between the patho-
physiologies seen in human CM and ECM, since P. berghei lacks
an HRPII gene. For example, tight junction protein relocalization
FIG 4 HRPII-mediated BBB compromise is independent of cell death. (A) HRPII results in late cell death, evidenced by nicked DNA in this TUNEL stain at 24
h postexposure to protein but not at 6 h. Cycloheximide (CHX) is a positive control for inducing cell death. (B) TEER measurements for in vitro model BBB left
untreated or treated with IFN- (10 ng), HRPII, or CHX (10 ng/ml) in the absence (blue) or presence (red) of an apoptosis inhibitor (Z-VAD-FMK; 10g/ml).
Data are means of results from 6 replicates SEM over three independent experiments.
Pal et al.















is not observed in ECM, suggesting that vascular leakage in the
rodent model occurs via a mechanism other than that observed in
humans (55, 56). HRPII-mediated barrier compromise depends
on caspase-1 activation of IL-1, and IL-1 levels in the cerebro-
spinal fluid of patients correlate with disease severity (57) whereas
IL-1 has been shown to be dispensable for the experimental CM
model (58).
Blocking HRPII action could be a prophylactic or therapeutic
strategy. Results of attempts in the 1980s to use HRPII as an im-
munogen in Aotus monkey vaccination trials were encouraging,
but results of follow-up studies were equivocal (59–61). New stud-
ies informed by the proposed role in cerebral malaria could lead to
development of a vaccine that prevents CM. HRPII-induced dam-
age might be minimized by targeting upstream components of the
pathway. Drugs targeting caspase-1 and IL-1 are already in clin-
ical use and could be considered for the treatment of cerebral
malaria.
Since causing CM is not likely to benefit the parasite, the ques-
tion of why P. falciparum has evolved and maintained the HRPII
gene is germane. One possible advantage for the parasite is that
triggering an inflammatory pathway leads to increased expression
of cytoadherence molecules on the endothelial surface. Cytoad-
herence allows the parasite to avoid clearance in the spleen and to
reside in a low-oxygen, high-carbon-dioxide environment. Para-
site sequestration in the cerebral vasculature is the hallmark fea-
ture of human CM and one that is largely absent in the murine
experimental CM model. Other cytokines such as tumor necrosis
factor alpha (TNF-) also upregulate adhesion molecules that are
receptors for P. falciparum-infected erythrocytes (62, 63).
Several new questions arise from this work. What does HRPII
bind, to initiate the inflammatory cascade? Is HRPII synergistic
with other P. falciparum virulence factors such as glycosylphos-
phatidylinositol (64)? Does HRPII affect endothelium in other
vascular beds in a similar manner? Our data suggest that HRPII
may contribute to malaria pathogenesis by modulating the BBB;
further mechanistic insight is needed to develop novel HRPII-
dependent pharmacological or vaccine-based strategies for dis-
ease control.
MATERIALS AND METHODS
Reagents. Bovine serum albumin (BSA) of reagent grade was from Sigma.
Lipopolysaccharide (LPS) from Escherichia coli O111:B4 was purchased
from List Biological Laboratories, Inc.
Antibodies. Mouse anti-HRPII (2G12), a generous gift from Diane
Taylor (University of Hawaii), was used at 1:100, goat anti-claudin-5
(from Santa Cruz; sc-17667) at 1:100, and VE-cadherin (Santa Cruz; sc-
52751) at 1:100. Five micrograms of anti-HRPII was used for neutraliza-
tion and was from Thermo Scientific (MA1-27094), and the isotype con-
trol (269) was generated as described previously (65). Rabbit anti-IL-1
(Rockland Immunochemical; 209-401-301) was used for neutralization.
Rabbit anti-GAPDH (anti-glyceraldehyde-3-phosphate dehydrogenase)
(Abcam; ab37168) was used at 1:1,000. Mouse anti-ICAM-1, anti-
VCAM-1, and anti-E-selectin (BD Biosciences; 555510, 555645, and
555648) were used at 1:500, 1:100, and 1:500 dilutions, respectively. Ar-
menian hamster anti-IL-1 (Leinco) was used for in vivo neutralization at
300 g/mouse.
Inhibitors. Triptolide (InvivoGen) was used at a final concentration
of 100 nM. Celastrol (InvivoGen) was used at a final concentration of
8.8 M. IL-1Ra (Sigma) was used at a final concentration of 500 ng/ml.
FIG 5 Human brain microvascular endothelial cells exposed to HRPII display an increase in levels of surface adhesion receptors. hCMEC/D3 cells were exposed
to BSA or HRPII (10g) for 24 h. Surface expression of cell surface adhesion receptor was measured by flow cytometry. (A and B) Levels of ICAM-1 expression
(A) and VCAM-1 expression (B) were significantly different as determined using a two-tailed t test (P 0.02 for each). (C) E-selectin expression results were not
significantly different between BSA treatment and HRPII treatment (P 0.94). Representative flow cytometry histograms from three independent experiments
in triplicate are shown below each bar graph.
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Caspase-1 inhibitor (Sigma, SML0429) was used at a final concentration
of 80 M.
HRPII purification. The coding sequence for the mature form of
HRPII was cloned into the pet-15b vector (Novagen) without a tag, ex-
pressed, and purified from E. coli lysate using nickel resin as previously
described (17). Protein was exchanged into 20 mM Tris–500 mM NaCl–
50 mM imidazole and loaded on a 5-ml nickel fast protein liquid chroma-
tography (FPLC) column (GE Healthcare). After washing with 60 column
volumes of 20 mM Tris–10 mM NaCl– 0.1% Triton X-114 to remove
residual LPS was performed, the column was washed with 20 column
volumes of loading buffer and eluted with loading buffer with 1 M imida-
zole. All preparations of HRPII were tested for residual LPS using a LAL
endotoxin test (Charles River Laboratories; R1708K). Antithrombin-
inhibitory activity was measured using a Factor Xa assay (17). Protein
concentration was determined by BCA assay (Fisher). Fully active, pure
preparations of HRPII protein were used in all experiments.
P. falciparum transfection. HRPII was PCR amplified from 3D7 par-
asite genomic DNA and cloned into TOPO vector (Life Technologies).
HRPII was inserted upstream of green fluorescent protein (GFP) in the
tEOE vector under control of the Hsp86 promoter. This vector is a mod-
ified form of tyEOE vector with the selectable marker human dihydrofo-
late reductase replacing the yeast dihydroorotate dehydrogenase selection
cassette (66). Dd2 transfections were performed as previously reported,
and parasites were selected with 10 nM WR99210 and cloned (67). Clones
were screened by PCR.
In vitro BBB cultures and TEER recordings. In vitro BBB endothelial
cell cultures were prepared as previously described (30). Briefly, 105 hC-
MEC/D3 cells (68) were cultured. Components for assessment (recombi-
nant or native protein, chemical inhibitors, and parasitized erythrocytes)
were added to the apical chamber immediately after determining baseline
values for each well. Resistance recordings were measured via chopstick
electrode with an EVOM voltmeter (World Precision Instruments). Re-
sistance values are expressed in ohms per square centimeter.
ShRNA knockdown and TEER. hCMEC/D3 cells (105) were cultured
on the apical side of a 0.9-cm2 fibronectin-coated polyethylene terephtha-
late filter insertion with 3.0-m porosity (BD Falcon). At 24 h later, cells
were transfected with 500 ng of shRNA and with Lipofectamine 3000 at a
1.5:1 ratio of Lipofectamine to DNA. Cells were then incubated for 36 h.
HRPII was then added, and TEER measurements were recorded over 24 h.
shRNAs for each gene were purchased from Origene as follows: for the
Myd88 gene, TG311320; for the NFB gene, TR318700; for the caspase-1
gene, TG305640; for the TLR9 gene, TR301076; for the TLR5 gene,
TR308792; and for the TLR2 gene, TR320553. Of the four shRNAs to each
gene received from the vendor, 2 to 3 of each were used based on silencing
efficiency in pilot studies. M5 for the MyD88 gene was from InvivoGen
(ksirna42-hmyd88 [M5 in this study]). Silencing efficiency for all assays
was determined by qRT-PCR.
Quantitative RT-PCR. Total RNA was isolated from treated or un-
treated cultured hCMEC/d3 cells using an RNeasy kit (Qiagen). To re-
move DNA, samples were treated with RNase-free DNase (Qiagen).
mRNA was quantified from total RNA by qRT-PCR as previously de-
scribed (69). Primetime quantitative PCR (qPCR) primers and probes
were purchased from IDT. GAPDH mRNA expression levels also were
determined, and normalization was performed using the threshold cycle
(CT) method as previously described (69).
Immunocytochemical analysis. Immunocytochemical analysis was
performed on hCMEC/D3 cells posttreatment with recombinant HRPII
or controls after a 10-min fixation in ice-cold methanol, followed by
FIG 6 Model for HRPII recognition by human brain endothelial cells and the intracellular pathway that leads to BBB leakage. (1) HRPII binds to an
as-yet-unidentified receptor (1) and may be internalized (2). Inflammasome adaptor proteins (likely ASC/CARD) associate with this endosome (3) and recruit
procaspase-1 (Pro-casp-1), which is auto-catalytically activated (4). Active caspase-1 can cleave pro-IL-1 into its mature form (5). Mature IL-1 is secreted (6),
such that it can then bind to the IL-1 receptor, IL-1R (7). Signaling through MyD88, IL-1R activates NFB (8), as does downstream signaling from the
inflammasome (9). NFB mediates transcription of inflammatory genes (10), resulting in a redistribution of tight junction and adherens junction proteins and
a compromised blood-brain barrier (11), as well as in an increase in levels of surface adhesion molecules (12).
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blocking in 3% BSA at room temperature. Cells then were incubated with
primary antibodies in blocking buffer, washed three times in phosphate-
buffered saline (PBS), and then incubated in secondary Alexa Fluor-
conjugated antibodies in blocking buffer at room temperature. Slides
were washed and then, in some cases, stained with To-Pro at a 1:500
dilution. Sections were sealed with ProLong Gold antifade, and then im-
ages were acquired by confocal microscopy (Carl Zeiss, USA).
Terminal deoxynucleotidyltransferase-mediated dUTP-biotin nick
end labeling (TUNEL) using a TUNEL assay kit (Roche; 12156792910)
was performed on paraformaldehyde-fixed hCMEC/D3 cells that had
been treated with 25g recombinant HRPII, control protein, or 3g LPS
for 6 to 24 h.
HRPII internalization. hCMEC/D3 cells were incubated with 1 g
HRPII–1 ml medium for 5 min at 0°C or 37°C. Cultures were washed and
incubated for another 25 min at the same temperature in medium lacking
HRPII. Control incubations lacked HRPII. Cells were fixed as before in
100% methanol and stained for HRPII using the 2G12 monoclonal Ab
(1:100 dilution) or secondary Ms-488 (1:1,000). Slides were sealed with
ProLong Gold antifade, and images were acquired.
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